Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Rev. Soc. Bras. Clín. Méd ; 19(3): 176-180, set 2021.
Article in Portuguese | LILACS | ID: biblio-1391950

ABSTRACT

A busca pelo corpo perfeito pode gerar graves consequências para a população que faz uso indiscriminado de substâncias visando a resultados rápidos. O caso relatado se refere a um pa- ciente de 21 anos, do sexo masculino, na cidade de São Paulo (SP), que apresentou quadro de síndrome colestática 15 dias após uso do anabolizante estanazolol para fins estéticos na ativi- dade física, evoluindo com hepatite medicamentosa grave, com aumento de transaminases, hiperrubilinemia às custas de bilirrubina direta e fatores de coagulação, sem resposta satis- fatória ao tratamento de suporte convencional, com melhora significativa após introdução de corticoterapia.


Searching for the perfect body image can cause severe conse- quences to the population using substances indiscriminately to reach results fast. The case reported refers to a male patient, 21 years old, from the city of São Paulo (SP), who developed choles- tatic syndrome 15 days after the use of the steroid Stanazol for aesthetic purposes during physical activity, progressing with se- vere drug-induced hepatitis, transaminases, bilirubin, and coagu- lation factors increase with no satisfactory response to the con- ventional support treatment, and significant improvement after the introduction of corticotherapy.


Subject(s)
Humans , Male , Adult , Young Adult , Stanozolol/toxicity , Chemical and Drug Induced Liver Injury/drug therapy , Glucocorticoids/therapeutic use , Anabolic Agents/toxicity , Ursodeoxycholic Acid/administration & dosage , Bilirubin/blood , Biopsy , Cholagogues and Choleretics/therapeutic use , Prednisone/administration & dosage , Cholestasis/diagnosis , Cholestasis/pathology , Cholesterol/blood , Cholestyramine Resin/administration & dosage , Catastrophic Illness , Chemical and Drug Induced Liver Injury/diagnosis , Chemical and Drug Induced Liver Injury/pathology , Transaminases/blood , Hydroxyzine/administration & dosage , Liver/pathology , Anticholesteremic Agents/therapeutic use , Antipruritics/therapeutic use
2.
Rev. bras. enferm ; 72(3): 600-608, May.-Jun. 2019. tab, graf
Article in English | BDENF, LILACS | ID: biblio-1013556

ABSTRACT

ABSTRACT Objective: To evaluate the effectiveness of the menthol package (lip hydration and ice popsicles) compared to a package of non-menthol measures (lip hydration and ice popsicles) as a way to relieve thirst in patients in the Anesthetic Recovery Room. Method: Randomized and parallel trial study, with 120 patients randomized patients in an experimental group - menthol measurements (n=59) and control group - measures without menthol (n = 61). Results: There was a significant (p<0.05) decrease in intensity, hydration, dryness and taste in the oral cavity between the three moments of assessment/intervention in the two groups. The difference was significant in the experimental group for thirst intensity at the second assessment/intervention point (p<0.05) after a single administration of the menthol package. Conclusion: There was a reduction in thirst intensity in both groups. Patients who received menthol packages showed a significant decrease in intensity after a single evaluation/intervention time. NCT: 02869139.


RESUMEN Objetivo: Evaluar la efectividad del paquete de medidas mentoladas (hidratación labial y picolé de hielo) comparado a un paquete de medidas no mentoladas (hidratación labial y picolé de hielo) como un método de alivio de la sed en pacientes en la Sala de Recuperación Post-Anestésica. Método: En un ensayo clínico aleatorizado, paralelo, 120 pacientes aleatorizados en un grupo experimental - medidas mentoladas (n=59) y un grupo control - medidas sin el mentol (n=61). Resultados: Hubo una disminución significativa (p<0,05) sobre la intensidad, hidratación, sequedad y gusto en la cavidad oral entre los tres momentos de evaluación/intervención en los dos grupos, indistintamente. La diferencia fue significativa en el grupo experimental para la intensidad de la sed en el segundo momento de la evaluación/intervención (p<0,05) después de una única administración del paquete de medidas mentoladas. Conclusión: Se encontró una reducción de la intensidad de la sed en los dos grupos. Los pacientes que recibieron las medidas mentoladas presentaron una disminución significativa de la intensidad después de un único momento de evaluación/intervención. NCT: 02869139.


RESUMO Objetivo: Avaliar a efetividade do pacote de medidas mentoladas (hidratação labial e picolé de gelo) comparado a um pacote de medidas não mentoladas (hidratação labial e picolé de gelo) como método de alívio da sede em pacientes na Sala de Recuperação Anestésica. Método: Ensaio clínico randomizado, paralelo, 120 pacientes aleatorizados em grupo experimental - medidas mentoladas (n=59) e grupo controle - medidas sem o mentol (n=61). Resultados: Houve diminuição significativa (p<0,05) sobre a intensidade, hidratação, secura e gosto na cavidade oral entre os três momentos de avaliação/intervenção nos dois grupos indistintamente. A diferença foi significativa no grupo experimental para intensidade da sede no segundo momento de avaliação/intervenção (p<0,05) após uma única administração do pacote de medidas mentoladas. Conclusão: Houve redução da intensidade da sede nos dois grupos. Os pacientes que receberam as medidas mentoladas apresentaram diminuição significativa da intensidade após um único momento de avaliação/intervenção. A NCT: 02869139.


Subject(s)
Humans , Male , Female , Adult , Thirst/drug effects , Menthol/pharmacology , Brazil , Linear Models , Statistics, Nonparametric , Bariatric Surgery/adverse effects , Bariatric Surgery/methods , Menthol/therapeutic use , Middle Aged , Antipruritics/therapeutic use , Antipruritics/pharmacology , Obesity/surgery
3.
Rev. chil. infectol ; 35(4): 445-447, ago. 2018. graf
Article in Spanish | LILACS | ID: biblio-978056

ABSTRACT

Resumen La infección por Strongyloides stercoralis es una parasitosis frecuente en las regiones tropicales y subtropicales, incluyendo la Amazonía peruana. En pacientes con inmunocompromiso, las manifestaciones clínicas son variadas y es frecuente la diseminación sistémica de la enfermedad, con compromiso de diversos órganos. Las manifestaciones cutáneas son infrecuentes y se describen en pacientes con algún grado de inmunosupresión. Se presenta el caso de un paciente inmunocompetente que desarrolló una púrpura reactiva por una infección por Strongyloides stercoralis crónica. Ante ello, es posible el compromiso cutáneo en pacientes inmunocompetentes con reagudización sistémica por este parásito.


Infection with Strongyloides stercoralis is a common parasitic infection in tropical and subtropical regions, including the Peruvian Amazon. The clinical manifestations are varied in patients with immunocompromised disease, and the systemic spread of the disease is frequent, compromising different organs and systems. Cutaneous manifestations are infrequent, being described in patients with some degree of immunosuppression. We present the case of an immunocompetent patient who developed a reactive purpura due to chronic Strongyloides stercoralis infection. Thus, skin involvement is possible in immunocompetent patients with systemic exacerbation due to this parasite.


Subject(s)
Humans , Animals , Male , Adult , Young Adult , Purpura/etiology , Purpura/immunology , Strongyloidiasis/complications , Strongyloidiasis/immunology , Purpura/drug therapy , Ivermectin/therapeutic use , Chlorpheniramine/therapeutic use , Immunocompromised Host , Strongyloides stercoralis/isolation & purification , Antiparasitic Agents/classification , Antiparasitic Agents/therapeutic use , Antipruritics/therapeutic use
4.
Rev. Soc. Bras. Clín. Méd ; 15(1): 61-67, 2017.
Article in English | LILACS | ID: biblio-833180

ABSTRACT

Pruritus represents one of the main clinical complaints in medical practice, and leads to significant impairment of life quality and some discomfort. Although the knowledge of its main primary and secondary etiologies is well-established in Internal Medicine, especially in Hepatology, its pathophysiological basis and specific therapeutic-directed approaches are still very complex and need a proper systematization for comprehension. This review aims to present the main current themes regarding the main clinical, pathophysiological, therapeutical and management aspects of cholestasis-associated pruritus. METHODS: The authors performed a wide review of practical clinical guidelines, review articles and original articles from manuscripts published and indexed in PubMed. CONCLUSIONS: Pruritus in cholestasis represents a complex symptom in clinical practice and can be secondary to different pathophysiological mechanisms; its early recognition allows a proper therapeutic approach in most cases.


O prurido representa uma das principais queixas clínicas na prática médica e origina importante comprometimento da qualidade de vida, além de desconforto. Apesar de suas principais etiologias primárias e secundárias serem de conhecimento bem estabelecido na Clínica Médica, em especial na Hepatologia, suas bases fisiopatológicas e os princípios da terapêutica específica direcionada são bastante complexos e necessitam uma sistematização adequada para sua compreensão apropriada. Esta revisão objetiva abordar os principais temas atuais referentes às bases clínicas, fisiopatológicas, terapêuticas e de manejo do prurido relacionados à colestase. Os autores realizaram ampla revisão em diretrizes clínicas práticas, artigos de revisão e publicações originais de artigos publicados e indexados na base PubMed. O prurido na colestase representa um sintoma complexo na prática clínica e pode decorrer de diferentes mecanismos fisiopatológicos secundários. Seu reconhecimento precoce possibilita a abordagem terapêutica apropriada na maioria dos casos.


Subject(s)
Humans , Antipruritics/therapeutic use , Cholestasis/complications , Pruritus/etiology , Pruritus/therapy , Skin/innervation , Neuralgia/physiopathology
5.
An. bras. dermatol ; 91(6): 791-798, Nov.-Dec. 2016. tab, graf
Article in English | LILACS | ID: biblio-837980

ABSTRACT

Abstract Among the wide range of symptoms neglected or resistant to conventional treatments in clinical practice, itch is emerging gradually as a theme to be studied. Itch complaints and the negative effects in the quality of life are observed in several medical fields. Although the partially obscure pathophysiology, some researchers decided to check and test the use of psychotropic drugs in resistant itch to conventional topical treatments and antihistamines. The objective of this study was to evaluate scientific evidence in psychotropic use in the treatment of itch of various causes. This is a systematic review of scientific literature. The following databases were used: PubMed, Web of Science, Scopus and Scielo. Randomized controlled trials that should focus on treatment with psychotropic drugs of pruritus of various causes were the inclusion criteria. All articles were analyzed by the authors, and the consensus was reached in cases of disagreement. Fifteen articles were included after analysis and selection in databases, with the majority of clinical trials focusing on psychopharmacological treatment of itch on account of chronic kidney disease. Clinical trials with psychotropic drugs mostly indicated significant improvement in the itching. In most trials of chronic kidney disease as basal disease for itch, greater effectiveness was observed with the use of psychotropic drugs compared with placebo or other antipruritic. However, the small amount of controlled trials conducted precludes the generalization that psychiatric drugs are effective for itch of various causes.


Subject(s)
Humans , Pruritus/drug therapy , Psychotropic Drugs/therapeutic use , Pruritus/etiology , Randomized Controlled Trials as Topic , Reproducibility of Results , Treatment Outcome , Cyclohexanecarboxylic Acids/therapeutic use , Doxepin/therapeutic use , gamma-Aminobutyric Acid/therapeutic use , Amines/therapeutic use , Kidney Diseases/complications , Antipruritics/therapeutic use
6.
Annals of Dermatology ; : 159-163, 2016.
Article in English | WPRIM | ID: wpr-185203

ABSTRACT

BACKGROUND: Severe pruritus is a challenging condition, and it is more difficult to deal with in older patients due to their limitations in taking oral medication because of underlying diseases, possible interaction with concurrent medications, and poor general condition. OBJECTIVE: We evaluated the efficacy and safety of naltrexone (Revia®), an opioid antagonist, in elderly patients with severe pruritus that was not easily controlled with conventional antipruritics. METHODS: Eighteen patients were enrolled, with a mean age of 73 years. They additionally received 50 mg of naltrexone per day for an average of 2 months. RESULTS: Using the visual analogue scale, 13 (72.2%) of 18 patients showed a "much improved" condition, reporting more than a 50% decrease in pruritus intensity. Sixteen (88.9%) showed symptomatic improvement, and only 2 (11.1%) had persistent pruritus. Five patients reported side effects including insomnia, fatigue, constipation, and anorexia. However, reactions were either limited to the first 2 weeks or well managed. CONCLUSION: Naltrexone could be an effective and safe alternative treatment option to control severe pruritus in older patients.


Subject(s)
Aged , Humans , Anorexia , Antipruritics , Constipation , Fatigue , Naltrexone , Pruritus , Sleep Initiation and Maintenance Disorders
7.
Annals of Dermatology ; : 563-577, 2015.
Article in English | WPRIM | ID: wpr-142530

ABSTRACT

BACKGROUND: Since the treatment guidelines for atopic dermatitis (AD) were released by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been several advances in AD management. OBJECTIVE: We aimed to establish updated evidence- and experience-based treatment guidelines for Korean AD. METHODS: We collected a database of references from relevant systematic AD reviews and guidelines regarding general AD management such as bathing and skin care, avoidance of exacerbating factors, education and psychosocial support, and the use of moisturizers and topical anti-inflammatory and antipruritic drugs. Evidence for each statement was graded and the strength of the recommendation for each statement classified. Thirty-nine KADA council members participated in three rounds of voting to establish an expert consensus of recommendations. RESULTS: Basic AD treatment includes proper bathing and skin care, avoidance of exacerbating factors, proper education and psychosocial support, and use of moisturizers. The regular use of moisturizer has a steroid-sparing effect and reduces relapse episodes. The short- and long-term use of topical corticosteroids and calcineurin inhibitors improves AD symptoms and should be encouraged to use in an active and proactive treatment. Wet-wrap therapy can be used for rapid recovery of acute exacerbation. Topical antipruritic drugs cannot be recommended for the treatment of AD. CONCLUSION: This report provides up-to-date evidence- and experience-based treatment guidelines for AD regarding general management and topical treatment. In addition, the average agreement scores obtained by a panel of experts based on the Korean healthcare system and patient adherence are presented.


Subject(s)
Adrenal Cortex Hormones , Antipruritics , Baths , Calcineurin , Consensus , Delivery of Health Care , Dermatitis, Atopic , Education , Korea , Patient Compliance , Politics , Recurrence , Skin Care
8.
Annals of Dermatology ; : 563-577, 2015.
Article in English | WPRIM | ID: wpr-142527

ABSTRACT

BACKGROUND: Since the treatment guidelines for atopic dermatitis (AD) were released by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been several advances in AD management. OBJECTIVE: We aimed to establish updated evidence- and experience-based treatment guidelines for Korean AD. METHODS: We collected a database of references from relevant systematic AD reviews and guidelines regarding general AD management such as bathing and skin care, avoidance of exacerbating factors, education and psychosocial support, and the use of moisturizers and topical anti-inflammatory and antipruritic drugs. Evidence for each statement was graded and the strength of the recommendation for each statement classified. Thirty-nine KADA council members participated in three rounds of voting to establish an expert consensus of recommendations. RESULTS: Basic AD treatment includes proper bathing and skin care, avoidance of exacerbating factors, proper education and psychosocial support, and use of moisturizers. The regular use of moisturizer has a steroid-sparing effect and reduces relapse episodes. The short- and long-term use of topical corticosteroids and calcineurin inhibitors improves AD symptoms and should be encouraged to use in an active and proactive treatment. Wet-wrap therapy can be used for rapid recovery of acute exacerbation. Topical antipruritic drugs cannot be recommended for the treatment of AD. CONCLUSION: This report provides up-to-date evidence- and experience-based treatment guidelines for AD regarding general management and topical treatment. In addition, the average agreement scores obtained by a panel of experts based on the Korean healthcare system and patient adherence are presented.


Subject(s)
Adrenal Cortex Hormones , Antipruritics , Baths , Calcineurin , Consensus , Delivery of Health Care , Dermatitis, Atopic , Education , Korea , Patient Compliance , Politics , Recurrence , Skin Care
9.
An. bras. dermatol ; 89(4): 570-575, Jul-Aug/2014. tab, graf
Article in English | LILACS | ID: lil-715546

ABSTRACT

BACKGROUND: notalgia paresthetica is a subdiagnosed sensory neuropathy presenting as a condition of intense itching and hyperchromic macule on the back that interferes with daily habits. OBJECTIVES: To determine the efficacy of treatment of notalgia paresthetica using oral gabapentin, assessing the degree of improvement in itching and influence on quality of life. Moreover, to evaluate the signs and symptoms associated with notalgia paresthetica. METHODS: We conducted an experimental, non-randomized, parallel, non-blinded study including 20 patients with clinical and histopathological diagnosis of notalgia paresthetica. After application of the visual analogue scale of pain adapted for pruritus and of the questionnaire of dermatology life quality index (DLQI), ten patients with visual analogue scale > 5 were given treatment with gabapentin at the dose of 300 mg/day for four weeks. The other ten were treated with topical capsaicin 0.025% daily for four weeks. After the treatment period, patients answered again the scale of itching. RESULTS: The use of gabapentin was responsible for a significant improvement in pruritus (p=0.0020). Besides itching and hyperchromic stain on the back, patients reported paresthesia and back pain. It was observed that the main factor in the worsening of the rash is heat. CONCLUSION: Gabapentin is a good option for the treatment of severe itching caused by nostalgia paresthetica. .


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Young Adult , Amines/therapeutic use , Back Pain/drug therapy , Cyclohexanecarboxylic Acids/therapeutic use , GABA Agents/therapeutic use , Paresthesia/drug therapy , Pruritus/drug therapy , Quality of Life , gamma-Aminobutyric Acid/therapeutic use , Antipruritics/therapeutic use , Back Pain/pathology , Capsaicin/therapeutic use , Paresthesia/pathology , Pruritus/pathology , Surveys and Questionnaires , Treatment Outcome , Visual Analog Scale
10.
Journal of Huazhong University of Science and Technology (Medical Sciences) ; (6): 504-509, 2014.
Article in English | WPRIM | ID: wpr-351049

ABSTRACT

Airway remodeling is an important pathological feature of asthma and the basis of severe asthma. Proliferation of airway smooth muscle cells (ASMCs) is a major contributor to airway remodeling. As an important Ca(2+) channel, transient receptor potential vanilloid 1 (TRPV1) plays the key role in the cell pathological and physiological processes. This study investigated the expression and activity of TRPV1 channel, and further clarified the effect of TRPV1 channel on the ASMCs proliferation and apoptosis in order to provide the scientific basis to treat asthmatic airway remodeling in clinical practice. Immunofluorescence staining and reverse transcription polymerase chain reaction (RT-PCR) were used to detect the expression of TRPV1 in rat ASMCs. Intracellular Ca(2+) was detected using the single cell confocal fluorescence microscopy measurement loaded with Fluo-4/AM. The cell cycles were observed by flow cytometry. MTT assay and Hoechst 33258 staining were used to detect the proliferation and apoptosis of ASMCs in rats respectively. The data showed that: (1) TRPV1 channel was present in rat ASMCs. (2) TRPV1 channel agonist, capsaicin, increased the Ca(2+) influx in a concentration-dependent manner (EC50=284.3±58 nmol/L). TRPV1 channel antagonist, capsazepine, inhibited Ca(2+) influx in rat ASMCs. (3) Capsaicin significantly increased the percentage of S+G2M ASMCs and the absorbance of MTT assay. Capsazepine had the opposite effect. (4) Capsaicin significantly inhibited the apoptosis, whereas capsazepine had the opposite effect. These results suggest that TRPV1 is present and mediates Ca(2+) influx in rat ASMCs. TRPV1 activity stimulates proliferation of ASMCs in rats.


Subject(s)
Animals , Rats , Antipruritics , Pharmacology , Apoptosis , Physiology , Bronchi , Cell Biology , Metabolism , Calcium Signaling , Physiology , Capsaicin , Pharmacology , Cell Proliferation , Myocytes, Smooth Muscle , Cell Biology , Metabolism , Rats, Sprague-Dawley , TRPV Cation Channels , Metabolism
11.
The Korean Journal of Parasitology ; : 413-419, 2013.
Article in English | WPRIM | ID: wpr-19712

ABSTRACT

The mainstay therapy against leishmaniasis is still pentavalent antimonial drugs; however, the rate of antimony resistance is increasing in endemic regions such as Iran. Understanding the molecular basis of resistance to antimonials could be helpful to improve treatment strategies. This study aimed to recognize genes involved in antimony resistance of Leishmania tropica field isolates. Sensitive and resistant L. tropica parasites were isolated from anthroponotic cutaneous leishmaniasis patients and drug susceptibility of parasites to meglumine antimoniate (Glucantime(R)) was confirmed using in vitro assay. Then, complementary DNA-amplified fragment length polymorphism (cDNA-AFLP) and real-time reverse transcriptase-PCR (RT-PCR) approaches were utilized on mRNAs from resistant and sensitive L. tropica isolates. We identified 2 known genes, ubiquitin implicated in protein degradation and amino acid permease (AAP3) involved in arginine uptake. Also, we identified 1 gene encoding hypothetical protein. Real-time RT-PCR revealed a significant upregulation of ubiquitin (2.54-fold), and AAP3 (2.86-fold) (P<0.05) in a resistant isolate compared to a sensitive one. Our results suggest that overexpression of ubiquitin and AAP3 could potentially implicated in natural antimony resistance.


Subject(s)
Humans , Amino Acid Transport Systems/genetics , Antimony/pharmacology , Antipruritics/pharmacology , Drug Resistance , Leishmania tropica/drug effects , Leishmaniasis, Cutaneous/parasitology , Protozoan Proteins/genetics , Ubiquitin/genetics
12.
An. bras. dermatol ; 87(5): 735-741, Sept-Oct. 2012.
Article in English | LILACS | ID: lil-651567

ABSTRACT

Pruritus is a symptom that may be associated with a wide array of diseases - skin diseases, systemic diseases or even those without a defined cause. According to its severity and evolution, it may compromise the patients' quality of life in a significant way. New therapeutic approaches, in which histamine release is not the main event, are being described for pruritus control. Therefore, taking into account the origin of the mediators of pruritus, we conducted a review of the available resources emphasizing that, although very important, anti-histamines are not the answer for every kind of pruritus.


Prurido é um sintoma que pode estar associado a uma gama ampla de patologias, sejam elas cutâneas, sistêmicas ou mesmo sem causa definida . Conforme sua intensidade e evolução pode comprometer de forma significativa a qualidade de vida dos pacientes. Novas abordagens terapêuticas estão sendo descritas para o controle do prurido, onde a liberação da histamina não é o fator principal. Assim, baseando-se na origem de seus mediadores, faz-se uma revisão desses recursos e ressalta-se que, embora de grande importância no arsenal terapêutico, os anti-histamínicos não são a panacéia para todos os tipos de prurido.


Subject(s)
Humans , Antipruritics/therapeutic use , Pruritus/drug therapy , Pruritus/classification , Pruritus/etiology , Pruritus/metabolism
13.
Article in Spanish | LILACS | ID: lil-651970

ABSTRACT

Introducción. Entre los síntomas que con mayor frecuencia presentan los pacientes con enfermedad renal crónica terminal en la terapia de reemplazo renal de tipo hemodiálisis y diálisis peritoneal, se encuentra el prurito urémico. Objetivo. Comparar la efectividad de los emolientes con la de la gabapentina en el manejo del prurito urémico y el impacto en la calidad de vida en los pacientes con enfermedad renal crónica terminal en terapia de reemplazo renal de tipo hemodiálisis y diálisis peritoneal, en el Servicio de Terapia Renal del Hospital Pablo Tobón Uribe, entre enero y abril de 2010. Metodología. Se realizó un ensayo clínico controlado de asignación aleatoria, sin cegamiento, en el que se administraron tratamientos con emolientes o gabapentina a grupos de pacientes con insuficiencia renal crónica y prurito, que acudieron al Servicio de Terapia Renal del Hospital Pablo Tobón Uribe, para recibir terapia de reemplazo renal, ya fuera hemodiálisis o diálisis peritoneal. Resultados. En ambos grupos se observó mejoría sustancial del prurito. En 15 pacientes que fueron tratados con gabapentina, se encontró una disminución de la intensidad del prurito, medido por la escala visual análoga, pasando de una media de 6,6 al inicio a una de 1,1 al final. Del mismo modo ocurrió con los 18 pacientes del grupo que recibió emolientes, pasando de una media de 5,2 al inicio a una de 1,3 al final. Con respecto a la evaluación de la calidad de vida, se observó diferencia únicamente para el dominio de la funcionalidad social en el grupo de emolientes entre la primera y segunda evaluación, sin apreciarse diferencias significantes en el grupo de gabapentina. Conclusión. Los pacientes experimentaron una mejoría estadísticamente significativa en el prurito con los dos tratamientos; sin embargo, cuando se compararon, no se observó diferencia significativa, por lo que no se puede aseverar, con el tamaño de muestra obtenido, que un tratamiento sea mejor que el otro. En cuanto a la calidad de vida, únicamente en el grupo de emolientes se apreció mejoría en el dominio de funcionalidad social.


Subject(s)
Antipruritics , Emollients , Kidney Failure, Chronic , Peritoneal Dialysis , Pruritus/therapy , Renal Dialysis , Uremia
14.
Indian J Biochem Biophys ; 2010 Apr; 47(2): 90-95
Article in English | IMSEAR | ID: sea-135249

ABSTRACT

The mast cell-mediated allergic reactions are involved in many allergic diseases, such as asthma, allergic rhinitis and sinusitis. Stimulation of mast cells initiates the process of degranulation, resulting in the release of mediators such as histamine and an array of inflammatory cytokines. In this report, we investigated the effect of gossypin (a biflavonoid) and suramin (a synthetic polysulphonated naphtylurea) on the mast cell-mediated allergy model, and studied the possible mechanism of their action. Both gossypin and suramin inhibited (P<0.001) compound 48/80-induced systemic anaphylaxis reactions, antiprurities (P<0.001) and reduced the histamine release in rats. Further, both showed significant (P<0.001) protection against rat peritoneal mast cells activated by compound 48/80. Thus, our findings provide evidence that gossypin and suramin inhibit mast cell-derived allergic reactions.


Subject(s)
Anaphylaxis/chemically induced , Anaphylaxis/drug therapy , Anaphylaxis/immunology , Animals , Anti-Allergic Agents/pharmacology , Anti-Allergic Agents/therapeutic use , Antipruritics/pharmacology , Antipruritics/therapeutic use , Ascitic Fluid/drug effects , Ascitic Fluid/metabolism , Bronchoalveolar Lavage Fluid , Disease Models, Animal , Flavonoids/pharmacology , Flavonoids/therapeutic use , Histamine Release/drug effects , Histamine Release/immunology , Hypersensitivity/blood , Hypersensitivity/drug therapy , Hypersensitivity/immunology , Hypersensitivity/metabolism , Mast Cells/drug effects , Mast Cells/immunology , Mast Cells/metabolism , Mice , Nitrogen Oxides/blood , Nitrogen Oxides/metabolism , Rats , Suramin/pharmacology , Suramin/therapeutic use , p-Methoxy-N-methylphenethylamine/pharmacology
15.
IJKD-Iranian Journal of Kidney Diseases. 2010; 4 (2): 137-140
in English | IMEMR | ID: emr-105450

ABSTRACT

Pruritus is one of the common problems in patients on hemodialysis. There are several causes for pruritus, and different treatment modalities are applied to control it. The aim of this study was to evaluate the therapeutic effect of capsaicin on pruritus, compared with placebo, in patients on hemodialysis. This randomized double-blinded cross-over clinical trial was performed on 34 patients on hemodialysis with uremic pruritus. The patients were divided into 2 groups, one group received capsaicin 0.03% and the other, placebo, for 4 weeks. Treatment was stopped for 2 weeks as washout period and continued as a cross-over technique. Pruritus scores were analyzed and compared. Thirty-four patients on long-term hemodialysis, 14 men and 20 women with a mean age of 57.0 +/- 18.6 years were studied. The mean of pruritus score before capsaicin treatment was 15.9 +/- 6.3, which was reduced to 6.4 +/- 3.9, 4.7 +/- 3.1, 3.2 +/- 2.9, and 2.5 +/- 2.5 on weeks 1 to 4, respectively [P < .001]. In the placebo group, pruritus score before treatment was 15.0 +/- 6.0 on average, and it was 11.7 +/- 5.8, 9.4 +/- 5.9, 7.9 +/- 5.5, and 7.2 +/- 5.5, respectively, on weeks 1 to 4 [P < .001]. There was no significant difference in pruritus scores before the treatment between the two groups, but after each week, the difference was significant [P < .001]. Repeated measurement test showed that decreasing in pruritus severity in the capsaicin group was more than that in the placebo group during treatment period [P < .001]. Capsaicin is a new safe and effective topical treatment for hemodialysis-induced pruritus in patients with end-stage renal disease


Subject(s)
Humans , Male , Female , Pruritus/drug therapy , Renal Dialysis/adverse effects , Administration, Topical , Double-Blind Method , Cross-Over Studies , Antipruritics/administration & dosage , Clinical Trials as Topic
16.
Article in English | AIM | ID: biblio-1256215

ABSTRACT

This study investigated antipruritic and anti-inflammatory effect of Centella asiatica extract in rats and anti-allergic in vitro using sheep (Capra hircus) serum method and compound 48/80 induced mast cell degranulation method; compared with standard drug ketotifen fumarate. In rats; extract of Centella asiatica administered orally was examined for anti-pruritic study and chlorpheniramine maleate was used as standard drug while carageenan paw induced inflammatory method was used for the antiinfammatory study. The results show that the extracts of Centella asiatica exhibited antiallergic; anti-pruritic and anti-inflammatory activities


Subject(s)
Anti-Allergic Agents , Anti-Inflammatory Agents , Antipruritics , Centella , Plant Extracts
17.
Acta Academiae Medicinae Sinicae ; (6): 27-30, 2009.
Article in Chinese | WPRIM | ID: wpr-259082

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the antipruritic mechanisms of pimecrolimus cream for women facial dermatitis.</p><p><b>METHODS</b>Topical pimecrolimus cream 1% was applied in 52 women patients with facial dermatitis. The Investigators Global Assessment (IGA) score, severity of pruritus (SP) scores, and a basic syntax and molecular substrate (molecular psychophysics) of nociception and pruriception established by temperature-sensitive transient receptor potential (TRP) channels were used to evaluate the clinical signs, severity of pruritus, and skin sensory phenomenon.</p><p><b>RESULTS</b>The IGA scores at day 1 and 4 of treatment and the SP score at day 1, 4, and 11 of treatment were significantly lower than the baseline scores before treatment (P < 0.05). Among these 52 patients, 28 (53.8%) showed positive capsaicin-like response (i.e., burning with consequent rapid amelioration of pruritus) at the application sites, 12 (23.1%) showed camphor-like response (i.e., warming with consequent rapid amelioration of pruritus), and 12 (23.1%) showed negative capsaicin-like response or negative camphor-like response.</p><p><b>CONCLUSIONS</b>Treatment with pimecrolimus cream 1% can rapidly and effectively improve the signs and symptoms of facial dermatitis in adult women patients. Pimecrolimus cream 1% may act on the transient potential vanilloid 1 (TRPV1) receptor in the skin sensory afferents to induce capsaicin-like response or camphor-like response and then desensitizes TRPV1 and rapidly inhibits or alleviate itching.</p>


Subject(s)
Adolescent , Adult , Female , Humans , Middle Aged , Young Adult , Administration, Topical , Antipruritics , Dermatitis , Drug Therapy , Face , Pruritus , Drug Therapy , Tacrolimus
18.
Rev. chil. dermatol ; 24(2): 128-131, 2008. tab
Article in Spanish | LILACS | ID: lil-567052

ABSTRACT

El prurito es la causa más común de consulta en Dermatología. En el presente articulo se hace una revisión de los estudios más relevantes sobre el prurito y se revisan la fisiopatogenia y la relación con enfermedades de distinto tipo. Es importante recalcar la relación entre el prurito y la respuesta del SNC, en lo que se ha llamado la inflamación neurobiológica. Establecemos una forma racional de enfrentar el prurito tanto desde el punto de vista de laboratorio como de terapéutica.


Pruritus is the most common symptom in dermatology. We present a review of the most relevant studies of pruritus its physiopathology and relations with other types of diseases. It is important to emphasize the relation between pruritus the CNS in what is known as neurobiological. Additionally we. Additionally we propase a rational means of facing pruritus from both laboratory and therapeutic perspectives.


Subject(s)
Humans , Pruritus/etiology , Pruritus/physiopathology , Pruritus/therapy , Anesthetics, Local/therapeutic use , Antipruritics/therapeutic use , Skin Diseases/complications , Nervous System Diseases/complications , Histamine/physiology , Neurogenic Inflammation/physiopathology , Neuropeptides/physiology , Phototherapy , Pruritus/classification , Mental Disorders/complications
19.
Annals of the Academy of Medicine, Singapore ; : 788-792, 2007.
Article in English | WPRIM | ID: wpr-348393

ABSTRACT

The neurophysiology of itch, the dominant symptom of skin disease, has previously received scant attention. Recent advances in the neurophysiology and molecular basis of itch include the use of microneurography to demonstrate the existence of a subset of itch-dedicated afferent C neurons distinct from neurons which transmit pain; use of functional positron emission tomography (PET) and magnetic resonance imaging (MRI) of the brain to reveal an itch-specific activation matrix, and new evidence of a functional "dialogue" between C neuron terminals and dermal mast cells in which recently described proteinase-activated receptor type 2 (PAR2) and transient receptor potential vanilloid 1 (TRPV1) receptors, proteases and endovanilloids play a major role. As a necessary prerequisite to diagnosis and management, a pathophysiologically based classification of itch is proposed. Recent advances in understanding of the pathomechanisms of itch of cholestasis include the role of opioids and opioid antagonists. Focusing on neurogenic itch (itch without visible rash), common causes are reviewed and guidelines for laboratory and radiological investigation are proposed. A stepwise approach to management of generalised itch is recommended, including broadband or narrow band ultraviolet (UV), tricyclics such as doxepin, opioid antagonists including naltrexone and selective serotonin reuptake inhibitors (SSRIs) such as paroxetine. For troublesome localised itches such as insect bite reactions, physical urticaria, lichen simplex chronicus or, less commonly, notalgia paraesthetica, brachioradial pruritus, local cooling devices which rely on the cooling action of dimethyl ethers on thermosensitive TRP voltage-sensitive ion channels are now commercially available for shortterm relief.


Subject(s)
Humans , Antipruritics , Therapeutic Uses , Diagnosis, Differential , Diagnostic Imaging , Methods , Neurons, Afferent , Physiology , Pruritus , Diagnosis , Therapeutics , Treatment Outcome , Ultraviolet Therapy , Methods
20.
Sudanese Journal of Dermatology. 2004; 2 (1): 9-15
in English | IMEMR | ID: emr-69027

ABSTRACT

About 20% of the population experience episodes of urticaria at least once in their lifetime. Type I hypersensitivity reactions may be involved in acute conventional and contact urticaria, but uncommonly in chronic urticaria. The diagnosis of urticaria can often be made only from the history. Patients may not present with skin lesions, so you should ask for history of drug intake and search for an infective focus. Nearly 50% of chronic idiopathic urticaria is associated with histamine-releasing autoantibodies. Episodes of urticaria lasting for more than 24 hours need to be evaluated for vasculitis and systemic disease. Antihistamines are the mainstay of treatment. Caution is to be taken while combining antihistamines with drugs like erythromycin and ketoconazole, for risk of cardiac arrhythmia [torsade de pointes]


Subject(s)
Pruritus/drug therapy , Antipruritics , Histamine H1 Antagonists , Urticaria/etiology , Urticaria/classification
SELECTION OF CITATIONS
SEARCH DETAIL